ITP three R's: regulation, routing, rituximab
- 15 August 2008
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 112 (4) , 927-928
- https://doi.org/10.1182/blood-2008-05-155770
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The Foxp3+ regulatory T cell: a jack of all trades, master of regulationNature Immunology, 2008
- Response to B-cell–depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpuraBlood, 2007
- Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high‐dose dexamethasomeEuropean Journal of Haematology, 2007
- Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpuraThrombosis Research, 2007
- Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpuraEuropean Journal of Haematology, 2006
- Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humansImmunological Reviews, 2006
- An essential role for Scurfin in CD4+CD25+ T regulatory cellsNature Immunology, 2003
- Foxp3 programs the development and function of CD4+CD25+ regulatory T cellsNature Immunology, 2003
- Natural versus adaptive regulatory T cellsNature Reviews Immunology, 2003
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003